Renewed interest in the potential benefits of psychedelic treatments has led to an upsurge in research. Is the first FDA approval of a psychedelic for therapeutic use on the horizon?
On this episode, Epstein Becker Green...more
The U.S. Food and Drug Administration (FDA) recently issued a final guidance document clarifying how the agency intends to regulate clinical decision support (CDS) software.
How has this document caused confusion for...more
In this Thought Leaders in Health Law® video, attorneys Neil Di Spirito, Alaap Shah, Jessika Tuazon, and Patricia Wagner from Epstein Becker Green look at the Food and Drug Administration’s (FDA’s) guidance on the...more